🔗 Permalink

Inventor profile of:

Daniel OFFEN

City:

Tel-Aviv

Country:

Israel

Published Applications:

Last publication date:

2025-07-03

Top Assignees for applications by Daniel OFFEN

The entities that hold a legal rights for patent applications filed by inventor OFFEN Daniel:

Ramot at Tel-Aviv University Ltd. 15 Tel-Aviv, Israel
YEDA RESEARCH AND DEVELOPMENT CO. LTD. 2 Rehovot, Israel
BrainStorm Cell Therapeutics Ltd. 2 Petach-Tikva, Israel
Technion Research and Development Foundation Limited 1 Haifa, Israel
BrainStorm Ceil Therapeutics Ltd. 1 Petach-Tikva, Israel
TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LIMITTED 1 Haifa, Israel

Recent patent applications by OFFEN Daniel

Daniel OFFEN from Tel-Aviv, IL has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-07-03

US20250215407A1

Chemistry; metallurgy

IMPROVED MACROMOLECULES AND METHODS FOR DESIGNING SAME

#2 | 2024-12-05

US20240398839A1

Human necessities

CANNABINOID-LIPID CONJUGATES, METHODS FOR PRODUCING THE SAME AND USES THEREOF

#3 | 2024-07-25

US20240245720A1

Human necessities

COMPOSITIONS COMPRISING EXTRACELLULAR VESICLES AND AN ACTIVE AGENT AND USES THEREOF

#4 | 2023-10-19

US20230330130A1

Human necessities

VESICLES COMPRISING A PTEN INHIBITOR AND USES OF SAME

#5 | 2023-04-13

US20230115463A1

Human necessities

CANNABIDIOL-CONTAINING COMPOSITIONS AND USES THEREOF

#6 | 2022-08-11

US20220251153A1

Chemistry; metallurgy

PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS

#7 | 2021-11-25

US20210361717A1

Human necessities

MESENCHYMAL CELL-DERIVED EXOSOMES TO TREAT NEUROLOGICAL DISORDERS

#8 | 2021-03-18

US20210077520A1

Human necessities

Vesicles comprising a PTEN inhibitor and uses of same

#9 | 2020-11-26

US20200370040A1

Chemistry; metallurgy

TREATMENT FOR PARKINSONIAN PATIENTS WITH MUTATIONS IN THE LRRK2 GENE

#10 | 2020-10-22

US20200331865A1

Chemistry; metallurgy

PERK inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins

#11 | 2020-01-09

US20200009180A1

Human necessities

METHODS OF TREATING ALZHEIMER'S DISEASE

#12 | 2019-07-11

US20190209621A1

Human necessities

Mesenchymal cell-derived exosomes to treat neurological disorders

#13 | 2019-07-04

US20190201452A1

Human necessities

Genetically modified muscle cells which express neurotrophic factors

#14 | 2019-01-10

US20190010130A1

Chemistry; metallurgy

Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins

#15 | 2018-11-22

US20180333458A1

Human necessities

Mesenchymal stem cells for the treatment of CNS diseases

#16 | 2018-04-26

US20180112185A1

Chemistry; metallurgy

Isolated cells and populations comprising same for the treatment of CNS diseases

#17 | 2017-05-04

US20170121381A1

Chemistry; metallurgy

Peptides for the treatment of neurodegenerative diseases

#18 | 2016-12-29

US20160375098A1

Human necessities

Mesenchymal stem cells for the treatment of CNS diseases

#19 | 2016-09-29

US20160279169A1

Human necessities

GENETICALLY MODIFIED MUSCLE CELLS WHICH EXPRESS NEUROTROPHIC FACTORS

InventorID:

1660970 ⎘